A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This will be a phase II trial of the combination of sunitinib and nivolumab in patients with
advanced, measurable, metastatic melanoma who harbor mutations in the KIT gene in their
tumors. It is a multi-center trial using the FDA-approved doses of both sunitinib and
nivolumab. Sunitinib will be provided by Pfizer. Endpoint is RECIST response rate and PFS.
Phase:
Phase 2
Details
Lead Sponsor:
California Pacific Medical Center Research Institute